# A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

> **NCT04044209** · PHASE2 · WITHDRAWN · sponsor: **Yale University**

## Conditions studied

- Myelodysplastic Syndromes
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** AG-120
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04044209
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-02-12
- **Primary completion:** 2021-09
- **Final completion:** 2023-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients were able to be screened nor enrolled.
- **Last updated:** 2022-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04044209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04044209, "A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04044209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*